HCV NS3-4A serine protease is a complex composed of NS3 and its cofactor NS4A.It is crucial for processing viral polyproteins, RNA replication, and virion formation and contains serine protease and NTPase/RNA helicase activities.
The HCV NS3/4A protease effectively cleaves and inactivates two key signaling molecules, mitochondrial antiviral signaling protein (MAVS) and Toll-IL-1 receptor domain-containing adaptor inducing IFN- (TRIF), in the sensory pathways that respond to HCV pathogen-associated molecular patterns (PAMPs) to induce interferons (IFNs). Chronic liver disease such as hepatic steatosis, fibrosis, cirrhosis, and hepatocellular carcinoma are all linked to HCV infection. One of the most appealing targets for the creation of specific antiviral agents against HCV has been the NS3-4A serine protease.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V0724 | Daclatasvir (BMS790052; EBP883) | 1009119-64-5 | Daclatasvir (formerly BMS-790052; EBP-883; trade name Daklinza), adirect-acting antiviral agent, is aselective inhibitor of HCV NS5A (nonstructural protein) with an EC50 of 9-50 pM. |
|
V3156 | Daclatasvir dihydrochloride | 1009119-65-6 | Daclatasvir dihydrochloride (BMS790052; EBP883; BMS-790052; EBP-883; Daklinza), the dihydrochloride salt of Daclatasvir, is a novel, highly potent and selective HCV NS5A protease inhibitor that has been approved in 2014 in EU for use in combination with sofosbuvir for the treatment of hepatitis C (HCV) by causing a decrease in serum HCV RNA levels. |
|
V0727 | Danoprevir ( ITMN191, R7227; RO5190591; RG7227) | 850876-88-9 | Danoprevir (formerly ITMN-191, R-7227; RO-5190591; RG 7227; RG-7227; trade name Ganovo) is an orally bioavailable and15-membered macrocyclic peptidomimetic inhibitor of the NS3/4A protease of hepatitis C virus (HCV) with IC50s in the range of 0.2-3.5 nM. |
|
V3702 | Elbasvir | 1370468-36-2 | Elbasvir (formerly known as MK-8742; MK8742; trade name Zepatier) is a potent NS5A (nonstructural protein 5A) inhibitor with anti-HCV (hepatitis C virus) activities against different HCV genotypes. |
|
V0726 | Lomibuvir (VX 222; VCH 222) | 1026785-59-0 | Lomibuvir (also called VX-22; S-1480; VCH222; VX22; S1480; VX222; VCH-222; VX-222) is a novel, potent and selective non-nucleoside inhibitor/NNI of hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase with IC50s in the range of 0.94-1.2 μM. |
|
V32613 | Mecarbinate | 15574-49-9 | Mecarbinate is an anti-HCV (hepatitis C virus) agent. |
|
V0073 | Ombitasvir (ABT267; Viekira Pak) | 1258226-87-7 | Ombitasvir (trade name; Viekira Pak; formerly known as ABT-267) is a novel and potent N-phenylpyrrolidine-based inhibitor of hepatitis C virus (HCV) NS5A with excellent potency, metabolic stability, and pharmacokinetics/PK. |
|
V2976 | Paritaprevir | 1216941-48-8 | Paritaprevir (formerly ABT-450; ABT450;Veruprevir; Viekirax;Viekira Pak; Technivie) is an acylsulfonamide analog and a component of the anti-HCV drug combination therapies: Viekira Pak (Paritaprevir+ombitasvir, ritonavir and dasabuvir) and Technivie (Paritaprevir+ombitasvir and ritonavir). |
|
V3914 | PIBRENTASVIR | 1353900-92-1 | Pibrentasvir (formerly ABT-530; ABT530, A-1325912; A1325912; trade name: Mavyret; Maviret), an HCV NS5A protease inhibitor, is an approved antiviral (anti-HCV) drug developed by Abbvie for treating HCV infections. |
|
V3663 | PSI-6206 | 863329-66-2 | PSI-6206 (also known asGS331007 and RO-2433), a deaminated derivative of PSI-6130, is a novel, potent and selective inhibitor of HCV NS5B polymerase. |
|
V3154 | Simeprevir | 923604-59-5 | Simeprevir (previously known asTMC43) is a competitive, reversible, macrocyclic, noncovalent inhibitor of the hepatitis C virus (HCV) NS3/4A protease. |
|
V0725 | Telaprevir ( LY-570310; VX950; MP-424) | 402957-28-2 | Telaprevir (also known as LY570310; VX-950; MP424; trade names: Incivek; Incivo), a marketed medication for HCV treatment, is a selective, and reversible peptidomimetic inhibitor of HCV NS3-4A serine protease with an IC50 of 0.35 μM. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
